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Objectives The purpose of this study was to investigate whether high levels of circulating proprotein convertase subtilisin
kexin type 9 (PCSK9) would increase cardiovascular risk in statin-treated patients.
Background Statins activate low-density lipoprotein (LDL) receptor gene expression, thus lowering plasma LDL levels. But
statins also activate the expression of PCSK9, a secreted inhibitor of the LDL receptor, thereby limiting their ben-
eficial effects.
Methods We have measured the plasma PCSK9 levels of 1,613 patients with stable coronary heart disease enrolled in
the Treating to New Targets study, a randomized trial that compared the efficacy of high- versus low-dose atorva-
statin. After a run-in period with atorvastatin 10 mg daily, patients were randomized to either continue with
10 mg or be up-titrated to 80 mg of atorvastatin, and followed during 5 years for major cardiovascular events
(MCVEs).
Results Circulating PCSK9 levels measured at randomization were predictive of clinical outcomes in the group random-
ized to remain on atorvastatin 10 mg (p  0.039), but not in the group that intensified atorvastatin treatment to
80 mg (p  0.24). Further, PCSK9 levels measured 1 year post-randomization did not change upon increase of
the statin dose.
Conclusions PCSK9 levels predict cardiovascular events in patients treated with low-dose atorvastatin. (A Study to
Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels [TNT];
NCT00327691) (J Am Coll Cardiol 2012;59:1778–84) © 2012 by the American College of Cardiology
Foundation
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EDThe concentration of low-density lipoprotein cholesterol
(LDL-C) is a significant predictor of atherosclerotic cardio-
vascular disease. This relationship is causal with overwhelm-
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cardiovascular risk. The extent of reduction in risk is a
function of how much LDL-C levels are reduced, with
several trials now clearly demonstrating greater benefits with
more intensive LDL-C lowering (1,2). This has led to
recommendations of strict LDL-C targets in high-risk
patients. Given that many people cannot achieve these
targets even with the highest dose of the most effective
statins, there is an obvious need for additional LDL-C
lowering therapies (3,4).
Statins inhibit the rate-limiting enzyme involved in
cholesterol biosynthesis, thereby decreasing intracellular
cholesterol levels. This activates a feedback mechanism that
up-regulates LDL receptor gene expression, resulting in
lower circulating LDL-C levels. However, statins also
up-regulate the expression of proprotein convertase subtil-
isin kexin type 9 (PCSK9), a known inhibitor of the LDL
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Areceptor. This up-regulation of PCSK9 has the potential to
limit the efficacy of statin-induced LDL-C lowering (5,6).
The reason for this is that PCSK9 binds to the LDL
receptor and directs it toward lysosomal degradation rather
than normal recycling to the cell membrane (7,8). Inhibiting
PCSK9 is thus a logical strategy for enhancing statin-
induced LDL-C lowering to maximize the reduction in
cardiovascular risk (9). Prospective studies are therefore
needed to determine whether PCSK9 holds a predictive
value for cardiovascular risk. We have conducted a case-
control study nested in the TNT (Treating to New Targets)
study, a randomized, controlled trial of patients with stable
coronary heart disease (CHD) to examine these questions.
Methods
Study design. The current study is a case-control substudy
nested in the TNT trial in which the data analysis was per
intention-to-treat principle. The study protocol and out-
comes of the TNT study have been published previously
(10,11). In brief, patients with clinically manifest CHD
commenced 8 weeks of open-label treatment with atorva-
statin 10 mg daily. After this run-in period, 10,001 patients
with LDL-C levels 130 mg/dl were randomized in a
double-blind design to therapy with either 10 or 80 mg of
atorvastatin per day. Patients were followed for a median of
4.9 years. The pre-planned selection of the nested case-
control study population is described in detail in a previous
publication (12). Only patients from whom informed con-
sent was obtained for measuring additional biomarkers were
eligible for this substudy. We included all 496 eligible
patients who developed major cardiovascular events
(MCVEs) during follow-up (cases). MCVEs were defined
as CHD death, nonfatal, non–procedure-related myocardial
infarction, resuscitated cardiac arrest, and fatal or nonfatal
stroke. We then randomly selected 1,117 patients who did
not develop MCVEs during follow-up (controls), matching
with the case patients within each treatment group. We
calculated that by assuming a common standard deviation of
150 ng/ml in plasma PCSK9 levels; the nested case-control
substudy had 90% power to detect a difference of 26 ng/ml
between the cases group and the controls group.
PCSK9 measurements. PCSK9 concentration was mea-
sured in fasting plasma samples collected at the time of
randomization (after the 8-week atorvastatin 10 mg run-in
period) and again 1 year after randomization. Blood samples
were collected in 10-ml lavender-top EDTA Vacutainer
(BD, Franklin Lakes, New Jersey) venous blood collection
tubes using standard phlebotomy practices. Immediately
after collection, tubes were gently inverted 6 times, and
centrifuged at 2,000 g for 10 min. Plasma samples were
transferred into 8-ml freezer vials, frozen at –70°C, shipped
on dry ice, and thawed for biomarker analysis (12). Lipid
levels had already been measured (10). PCSK9 concen-
trations were measured in duplicate after a second thaw,
RE
TRusing the CY-8079 enzyme-linked immunosorbent assay(ELISA) kit (Cyclex, Nagano,
Japan), as per the manufacturer’s
instructions. We determined the
inter- and intraplate variability to
be less than 5.1% and 4.3%, re-
spectively. To ascertain the sta-
bility of PCSK9 in frozen plasma
samples, we subjected 6 ran-
domly chosen aliquots stored at
–80°C to 2 freeze-thaw cycles
over 4 months. PCSK9 levels
were measured and found to be
within the assay intraplate vari-
ability range. PCSK9 concentra-
tion of plasma aliquots from a
compound heterozygote individ-
ual lacking PCSK9 (Generously
provided by Dr. Jay Horton) was measured and found below
the detection threshold.
Statistical analyses. Patient characteristics at randomiza-
tion were compared between treatment groups or between
outcomes using a chi-square test for categorical variables,
and a Wilcoxon rank sum test for continuous variables.
Similarly, characteristics of substudy patients at time of
randomization were compared between those who did and
those who did not experience a cardiovascular event during
the study follow-up. Changes in PCSK9 levels were tested
with a signed rank test, and compared between treatment
groups with a Wilcoxon rank sum test. Spearman rank
correlation analyses were used to assess the correlation
between PCSK9 and lipids. The association between
PCSK9 levels at time of randomization and the primary
outcomes was assessed using a Cox proportional hazards
model, using time to outcome as the dependent variable.
The association between PCSK9 levels at year 1 and
subsequent primary event was analyzed similarly while
excluding patients with any prior event during year 1.
Baseline PCSK9 levels measured at time of randomization
were not included in the model. Hazard ratios (HRs) were
calculated using an unadjusted model and also a multivariate
model adjusted for age, sex, treatment group, smoking
status (current smoker or not), hypertension, diabetes, body
mass index, and LDL-C levels. To examine whether the
association between PCSK9 and outcome differed between
patients who did or did not intensify atorvastatin treatment,
the treatment by PCSK9 interaction was examined in the
same analysis models incorporating the interaction term.
Analyses were also repeated within each individual treat-
ment group. To compare the strength of association be-
tween PCSK9 and MCVE relative to other biomarkers,
including lipids and lipoprotein cholesterol, the van der
Waerden normal scores based on ranks were calculated for
each of the biomarker by taking the inverse cumulative
normal (PROBIT) function of ri/(n 1). These scores were
then used in the Cox proportional hazards model to assess
Abbreviations
and acronyms
CHD  coronary heart
disease
HDL-C  high-density
lipoprotein cholesterol
HR  hazard ratio
IQR  interquartile range
LDL-C  low-density
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PCSK9  proprotein
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AIn the Cox proportional hazards analyses, PCSK9 level
was not log-transformed, as the transformation did not
improve the normality (the Shapiro-Wilk statistics wors-
ened slightly from 0.94 to 0.84). In a Supremum test for
proportional hazards assumption, the proportional hazards
assumption was not violated. We considered a p value
0.05 to indicate statistical significance.
Results
Patient population and characteristics. Characteristics of
patients in the present study were similar to those in the
entire TNT population (12). Of the 496 patients who
experienced an MCVE, 110 (22.8%) died due to a CHD
event, 288 (58.1%) had a nonfatal myocardial infarction,
142 (28.6%) had a stroke, and 23 (4.6%) were resuscitated
after cardiac arrest. This distribution mirrors that of the 982
patients who suffered an event in the entire TNT popula-
tion, in which 23% died due to a CHD event, 56% had
nonfatal myocardial infarction, 28% had stroke, and 5%
were resuscitated after cardiac arrest. Of the 496 MCVEs
that occurred during follow-up, 107 (22%) occurred in the
first year. The characteristics of patients by treatment
groups and by subgroups who experienced an MCVE and
those who did not are shown in Table 1. Baseline charac-
teristics were similar in the group randomized to remain on
10 mg atorvastatin and in the group randomized to receive
atorvastatin 80 mg. Patients who had an MCVE during the
trial were on average older and more likely to have hyper-
tension and/or diabetes at baseline compared with those
who did not experience an event. At randomization, levels
of LDL-C and triglycerides were significantly higher and
levels of high-density lipoprotein cholesterol (HDL-C)
were significantly lower in cases than in controls. Changes
Patient Characteristics at Time of Randomization*Table 1 Patient Characteristics at Ti e of Randomization*
Atorvastatin 10 mg
All With MCVE Without MCVE p
n 849 262 587
Age, yrs 61 9 62 8 60 9
Male 700 (82) 213 (81) 487 (83)
Current smoker 121 (14) 49 (18) 72 (12)
Hypertension 470 (55) 172 (66) 298 (51)
Diabetes mellitus 136 (16) 64 (24) 72 (12)
Total cholesterol, mg/dl 174 24 176 25 173 24
Delta TC, mg/ml 71 22 73 24
LDL cholesterol, mg/dl 97 18 100 18 96 18
Delta LDL-C, mg/ml 63 21 66 21
HDL-C, mg/dl 46 10 44 9 47 10
Delta HDL-C, mg/ml 1 4 1 5
Triglycerides, mg/dl 136 (102–186) 143 (107–197) 133 (100–181)
Delta TG, mg/ml 47 61 46 61
PCSK9, ng/ml 309 (228–396) 318 (240–425) 305 (221–384)
Values are mean  SD, n (%), or median (interquartile range). Deltas indicate changes in plasm
participants had been on 10 mg atorvastatin for at least 8 weeks (run-in period). †p value for pati
randomized to remain on 10 mg atorvastatin versus patients up-titrated to 80 mg atorvastatin.
RE
TRHDL-C  high-density lipoprotein cholesterol; LDL-C  low-density lipoprotein cholesterol; MCVE  m
cholesterol; TG  triglycerides.in plasma lipids over the 8-week run-in period were similar
in cases and controls, with LDL-C levels reduced by 38%
and 40%, respectively.
Plasma PCSK9 levels at randomization. PCSK9 levels at
randomization had a slight right-skewed distribution and
ranged between 1 and 1538 ng/ml (Fig. 1). Median PCSK9
levels at randomization were similar (p  0.89) for the
roup randomized to remain on atorvastatin 10 mg (309
g/ml, interquartile range [IQR]: 228 to 396 ng/ml) and the
roup randomized to receive 80 mg of atorvastatin daily
309 ng/ml, IQR: 228 to 397 ng/ml). Nor were median
CSK9 levels at randomization significantly different be-
ween cases (311 ng/ml, IQR: 236 to 401 ng/ml) and
ontrols (308 ng/ml, IQR: 226 to 394 ng/ml; p  0.42). In
he group randomized to remain on atorvastatin 10 mg
hroughout the trial, PCSK9 levels measured at the time of
andomization were higher in patients who subsequently
uffered a MCVE during follow-up (318 ng/ml, IQR: 240
o 425 ng/ml in the cases vs. 305 ng/ml, IQR: 221 to 384
g/ml in the controls; p 0.026) (Table 1). Similarly, in the
roup randomized to the 10-mg dose, those who experi-
nced a major CHD event during follow-up had higher
edian PCSK9 levels at randomization (322 ng/ml, IQR:
44 to 439 ng/ml) than controls (305 ng/ml, IQR: 221 to
84 ng/ml; p 0.025). In contrast to the group randomized
to remain on 10 mg atorvastatin, plasma PCSK9 levels at
randomization did not differ between the case and controls
in the group that intensified atorvastatin treatment to 80 mg
(300 ng/ml, IQR: 233 to 369 ng/ml vs. 313 ng/ml, IQR:
227 to 410 ng/ml; p  0.22).
PCSK9 levels after 1-year treatment. PCSK9 levels dis-
tribution after 1 year of treatment was similar to that
observed at time of randomization and did not differ
Atorvastatin 80 mg
p Value‡† All With MCVE Without MCVE p Value†
764 234 530
9 62 8 63 8 61 8 0.0027 0.15
639 (84) 199 (85) 440 (83) 0.49 0.53
110 (14) 44 (19) 66 (12) 0.054 0.98
1 425 (56) 144 (62) 281 (53) 0.029 0.91
1 122 (16) 50 (21) 72 (14) 0.0068 0.98
174 23 176 24 174 23 0.23 0.89
71 22 71 23 0.60
2 97 17 100 16 96 17 0.0056 0.89
63 21 65 20 0.28
2 47 11 45 11 48 11 0.0004 0.32
0.5 5 1 6 0.10
133 (99–181) 135 (98–188) 132 (99–179) 0.46 0.14
46 52 44 59 0.62
309 (228–397) 300 (233–369) 313 (227–410) 0.22 0.89
s after the 8-week run-in period (i.e., before randomization). *At the time of randomization, all
o experienced an event versus those who did not in both treatment groups. ‡p value for patients
CT
EDValue
0.000
0.56
0.046
0.000
0.000
0.080
0.147
0.006
0.89
0.000
0.36
0.024
0.19
0.026
a lipid
ents whajor cardiovascular event(s); PCSK9  proprotein convertase subtilisin kexin type 9; TC  total
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A
between both treatment arms of the study (Fig. 1). Overall,
PCSK9 levels 1 year after randomization did not differ
significantly between the 10 and 80 mg atorvastatin treat-
ment groups (318 ng/ml, IQR: 231 to 417 ng/ml vs. 311
ng/ml, IQR: 231 to 407 ng/ml; p  0.82). Nor were there
significant differences between the 2 treatment groups in
terms of change in PCSK9 between the randomization and
1-year post-randomization levels (not shown). Among the
total group and both treatment arms, there were no signif-
icant correlations between plasma PCSK9 levels (at ran-
domization and 1 year), LDL-C (at randomization and 1
year), HDL-C (at randomization and 1 year), triglycerides
(at randomization and 1 year), lipid changes between
pre–run-in and randomization, and lipid changes between
randomization and 1-year post-randomization. PCSK9 lev-
els did not differ significantly between sexes. There were
also no significant correlations between PCSK9 levels at
randomization and age or body mass index (not shown).
Figure 1 Frequency Distribution of PCSK9 Plasma Levels in the
Distribution of proprotein convertase subtilisin kexin type 9 (PCSK9) levels in the
domization (B), in the 10 mg atorvastatin group after 1 year of treatment (C), and
Relationship Between PCSK9 Levels at Randomization* and Risk oTable 2 Relationship Between PCSK9 Levels at Randomization
All Patients
HR (95% CI)† p Value
MCVE
Unadjusted model 1.02 (0.97–1.08) 0.45
Adjusted model 1.03 (0.97–1.09) 0.39
Major coronary events
Unadjusted model 1.05 (0.98–1.12) 0.18
Adjusted model 1.05 (0.98–1.12) 0.18
Adjusted model incorporated age, sex, treatment group, smoking status, hypertension, diabetes, b
proprotein convertase subtilisin kexin type 9 (PCSK9) interaction was 0.03 for major cardiovascula
RE
TRparticipants had been on 10 mg atorvastatin for at least 8 weeks. †Per 100 ng/ml increment in the PCS
CI  confidence interval; HR  hazard ratio.Relationships between PCSK9 plasma levels measured at
time of randomization or after 1 year of treatment and
risks of major cardiovascular or CHD events. Table 2
shows the relationship between PCSK9 levels at random-
ization and risk of MCVE or CHD events. Plasma PCSK9
levels measured at randomization were not associated with
the risk of MCVE or CHD events (HR per 100 ng/ml
increase: 1.03 [95% CI: 0.97 to 1.09], p 0.39; HR per 100
ng/ml increase: 1.05 [95% CI: 0.98 to 1.12], p  0.18,
respectively). The treatment by PCSK9 interaction on
MCVE was statistically significant (p 0.03), however, the
treatment by PCSK9 interaction on CHD was not statisti-
cally significant (p  0.11). Separate analyses were per-
formed for each treatment group. In the group randomized
to remain on 10 mg atorvastatin, PCSK9 levels measured at
randomization correlated significantly with both MCVE
and major CHD events (HR per 100 ng/ml increase: 1.08
[95% CI: 1.04 to 1.16], p  0.039; HR per 100 ng/ml
Trial
atorvastatin group at randomization (A), in the 80 mg atorvastatin group at ran-
80 mg atorvastatin group after 1 year of treatment (D).
VE and Major Coronary EventsRisk of MCVE and Major Coronary Events
Atorvastatin 10 mg Atorvastatin 80 mg
(95% CI)† p Value HR (95% CI)† p Value
1.03–1.18) 0.0082 0.92 (0.84–1.01) 0.075
1.04–1.16) 0.039 0.95 (0.86–1.04) 0.24
1.03–1.21) 0.008 0.96 (0.87–1.06) 0.39
1.005–1.19) 0.038 0.99 (0.89–1.10) 0.84
ss index, and low-density lipoprotein cholesterol levels at randomization. p Value for treatment by
s (MCVE) and 0.11 for major coronary events (adjusted model). *At the time of randomization, all
CT
EDTNT
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Aincrease: 1.09 [95% CI: 1.005 to 1.19], p  0.038, respec-
tively). In contrast, in the group randomized to receive
atorvastatin 80 mg, PCSK9 levels measured at randomiza-
tion predicted neither subsequent MCVE nor CHD events
(HR per 100 ng/ml increase: 0.95 [95% CI: 0.86 to 1.04],
p  0.24; HR per 100 ng/ml increase: 0.99 [95% CI: 0.89
to 1.10], p  0.84, respectively) (Table 2). In the atorva-
tatin 10 mg treatment arm of the study, the predictive value
f PCSK9 at randomization on CHD and MCVE was
aximal (HR per 100 ng/ml increase: 1.45 [95% CI: 1.02 to
.06]; HR per 100 ng/ml increase: 1.33 [95% CI: 0.99 to
.78], respectively) in the group of patients with the highest
CSK9 levels, as shown in Figure 2. In this analysis
Figure 2 Relationship Between PCSK9 Levels and
Cardiovascular Risk in the TNT Study
Relationship between proprotein convertase subtilisin kexin type 9 (PCSK9)
levels stratified by tertiles at time of randomization and the risk of coronary
heart disease (CHD) (top) or major cardiovascular events (MCVE) (bottom) in
the group randomized to remain on 10 mg atorvastatin and the group
up-titrated to 80 mg atorvastatin. Hazard ratios per 100 ng/ml increment in
the PCSK9 concentration and 95% confidence intervals are indicated.
Relationships of MCVE and Major Coronary Events to PCSK9 LevelTable 3 Relationships of MCVE and Major Coronary Events to P
All Patients
HR (95% CI)* p Value
MCVE
Unadjusted model 0.97 (0.90–1.04) 0.41
Adjusted model 0.98 (0.91–1.06) 0.65
Major coronary events
Unadjusted model 1.002 (0.92–1.09) 0.097
Adjusted model 1.02 (0.93–1.11) 0.69
p value for treatment by PCSK9 interaction between treatment and clinical outcomes was 0.76 fo
ET
Rconcentration. Adjusted model incorporated age, sex, treatment group, smoking status, hypertension, dia
Abbreviations as in Table 2.stratified by tertiles, we observed a dose-effect relationship
between plasma PCSK9 levels at randomization and their
predictive value for CHD. Levels of PCSK9 measured after
1 year of treatment with atorvastatin were not predictive of
subsequent MCV or CHD events in either the combined
groups or in the separate treatment groups (Table 3). We
also assessed the prognostic value of PCSK9 levels measured
at randomization for MCVE after year 1 by excluding the
107 patients who had an event during year 1. Baseline
PCSK9 was no longer significant in predicting events
post–year 1 in either treatment arm of the study.
Relationship of PCSK9 with MCVE compared with
other biomarkers. Table 4 compares the strength of asso-
ciation between PCSK9 and MCVE with the strength of
association between other biomarkers and MCVE in the
atorvastatin 10 mg arm of the study. The association
between circulating PCSK9 levels and clinical outcomes in
this group was smaller than that observed between either
LDL-C or HDL-C and MCVE, but larger than that
observed between either triglycerides or C-reactive protein
and MCVE.
Discussion
This nested case-control substudy of the TNT trial was
designed to investigate the association between lipid and
nonlipid biomarkers and the risk of MCVE in statin-treated
ear After Randomization9 Levels 1 Year After Randomization
Atorvastatin 10 mg Atorvastatin 80 mg
(95% CI)* p Value HR (95% CI)* p Value
(0.86–1.07) 0.48 0.97 (0.88–1.08) 0.62
(0.89–1.12) 0.91 0.97 (0.87–1.09) 0.64
(0.90–1.15) 0.84 0.99 (0.88–1.11) 0.86
(0.92–1.21) 0.46 0.99 (0.87–1.12) 0.83
and 0.49 for major coronary events (adjusted model). *Per 100 ng/ml increment in the PCSK9
Relationship of MCVE to Plasma BiomarkerL vels at Randomization for Individualsandomized to Remain n 10 mg Atorvastatin*
Table 4
Relationship f MCVE to Pl ma Biomarker
Levels at Randomization for Individuals
Randomized to Remain on 10 mg Atorvastatin*
Biomarker
Unadjusted Model Adjusted Model
HR (95% CI)† p Value HR (95% CI)† p Value
PCSK9 1.191 (1.035–1.371) 0.015 1.155 (1.003–1.330) 0.047
LDL-C 1.163 (1.034–1.309) 0.012 1.179 (1.044–1.333) 0.0082
HDL-C 0.769 (0.676-0.874) 0.0001 0.779 (0.679–0.894) 0.0004
Triglycerides 1.170 (1.013–1.351) 0.033 1.089 (0.936–1.266) 0.27
CRP 1.163 (1.034–1.308) 0.012 1.085 (0.963–1.223) 0.18
Adjustment was done for age, sex, smoking status, hypertension, diabetes, and body mass index.
*At the time of randomization, all participants had been on 10mg atorvastatin for at least 8 weeks.
†HR (95% CI) per unit increment in the van der Waerden normal scores of the biomarker
concentration at randomization in a Cox proportional hazards model.
CI confidence interval; CRP C-reactive protein; HDL-C high-density lipoprotein cholesterol;
R  hazard ratio; LDL-C  low-density lipoprotein cholesterol; MCVE major cardiovascular
vent; PCSK9  proprotein convertase subtilisin kexin type 9.
CT
EDs 1 YCSK
HR
0.96
0.99
1.02
1.06
r MCVE
betes, body mass index and low-density lipoprotein cholesterol levels at randomization.
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Astable CHD patients (12). Using the same approach and the
same subpopulation, we have tested the possibility that
plasma PCSK9, a functional inhibitor of the LDL receptor,
is associated with the incidence of cardiovascular events.
Circulating PCSK9 levels measured at randomization were
predictive of clinical outcomes in the group randomized to
remain on atorvastatin 10 mg, but not in the group that
intensified atorvastatin treatment to 80 mg. After 1 year of
treatment, PCSK9 levels did not change significantly and
were no longer predictive of clinical events in both groups.
It is well established in humans and animal models that
statin treatment increases plasma PCSK9 levels and con-
versely that attenuation of PCSK9 function enhances the
hypolipemic effects of statins (13–16). For example, high
doses of atorvastatin have been reported to increase circu-
lating PCSK9 levels by 34% in 12 dyslipemic patients
treated with 40 mg daily for 16 weeks (15), and by 45% in
74 normolipemic non-CHD individuals treated with 80 mg
for 4 weeks (17). It was therefore expected that up-titration
from 10 to 80 mg atorvastatin would increase plasma
PCSK9 levels in the present study, as mentioned in a recent
report indicating that when atorvastatin dose was increased
from 5 to 80 mg daily, plasma PCSK9 levels increased on
average by 30% in 53 dyslipidemic patients (18). To our
surprise, we found that plasma PCSK9 levels were similar at
randomization and 1 year later after up-titration to 80 mg.
Major differences in study design could explain these ap-
parent discrepancies. The TNT substudy has potential
limitations in terms of design, methods, and statistical
approach (12). For example, all patients enrolled in the
TNT trial, including those in the biomarker study, had a
history of CHD. It is therefore likely that their statin-naive
plasma PCSK9 levels, a parameter that was not measured
here, were on average higher than those of the normoli-
pemic individuals or of the asymptomatic dyslipemic pa-
tients included in the studies mentioned previously (17,18).
In addition, inclusion in the TNT study was limited to
those who achieved LDL-C levels below 130 mg/dl with
atorvastatin 10 mg treatment for 4 weeks, to exclude
patients with poor compliance. This has led to an under-
representation of individuals who respond poorly to atorva-
statin, likely also those with a high PCSK9 activity. As a
result, LDL-C levels were sharply reduced (by 40% on
average) among patients randomized in the TNT cohort.
Because statins up-regulate PCSK9 expression, it is likely
that 10 mg atorvastatin daily for 8 weeks was sufficient to
maximally increase circulating PCSK9 levels to a plateau in
this cohort.
It is also well established that as a functional inhibitor of
the LDL receptor, plasma PCSK9 is positively correlated
with LDL-C in humans (18–21). Because statins simulta-
neously up-regulate LDL receptor and PCSK9 expression,
it is not surprising that statin treatment disrupts the positive
correlation between serum PCSK9 and LDL-C (17). In line
with this, we did not observe any significant correlation
RE
Rbetween circulating PCSK9 and plasma lipids measured atrandomization, or changes in plasma lipids upon up-
titration to 80 mg. Recent reports have also indicated that
there is no significant inverse correlation between baseline
PCSK9 and changes in LDL-C in response to statin in 2
large cohorts (17,21). The absence of correlation between
LDL-C and plasma PCSK9 upon increasing statin dose can
also be explained by the opposite regulatory patterns that
statins exert: 1) on PCSK9 gene expression; and 2) on the
expression of a novel physiological inhibitor of the LDL
receptor, the E3 ubiquitine ligase Idol in vitro (22,23).
Indeed, both PCSK9 and Idol reduce cellular LDL receptor
protein levels by promoting its degradation via 2 distinct
molecular pathways that are independent and additive in
embryonic stem cells (24). Whether the Idol pathway is also
altered upon statin treatment remains to be demonstrated in
vivo (24).
The observation that plasma levels of PCSK9 measured
at randomization appears to be predictive of future cardio-
vascular outcomes in the group maintained on 10 mg
atorvastatin, but not in patients up-titrated to receive 80 mg,
further extends the observation that genetic variation in
PCSK9 associates with statin-induced LDL-C lowering in
the entire TNT cohort (25). Together, these findings have
potential implications for future strategies in secondary
prevention of CHD: 1) PCSK9 inhibitors could reveal an
interesting therapeutic approach on top of statins to reduce
CHD risk in particular for patients in whom increase of
statin dose is not feasible; and 2) it can be argued that
high-dose atorvastatin eliminates the increased risk associ-
ated with high plasma PCSK9 levels, but this does not rule
out the possibility that adding a PCSK9 inhibitor on top of
high-dose atorvastatin may eventually provide incremental
clinical benefit. It can be hypothesized that because the
amount of circulating PCSK9 is not fully reflective of
PCSK9 activity in vivo (21,26,27), inhibition of PCSK9
may have more beneficial effects than expected from the
predictive value of PCSK9 plasma levels.
Considerable progress has been made in the development
of PCSK9 inhibitors in the last few years (28–31). In this
regard, our results raise the possibility that PCSK9 inhibi-
tion may further decrease cardiovascular risk in statin-
treated patients. Ultimately, however, this remains to be
tested and randomized trials with PCSK9 inhibition in
statin-treated patients are eagerly awaited.
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